Seres Therapeutics, Inc. MCRB
1.44 USD +0.03 (+2.13%)
Regular-session close
1.46 +0.02 +1.39%
After hours · Nov 18, 4:00 PM ET
1.41 Day range 1.58
1.30 52-week range 29.98
- YTD
- -90.32%
- 1 year
- -94.17%
News
benzinga.com Seres Therapeutics Q3 EPS $(1.63) Misses $(1.00) Estimate, Sales $593.000K Miss $6.350M Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.63) per share which missed the analyst consensus estimate of $(1.00) by 63 percent. This is a 273.4 percent decrease over earnings of…
benzinga.com Seres Therapeutics Announces Publication Of Results From Phase 1b Clinical Study Of SER-155 In Adults Undergoing Allogeneic Hematopoietic Cell Transplantation In Nature Medicine Issue Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placeboTranslational data…
benzinga.com On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026 On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and…
